Tuberculosis Biomarker and Surrogate Endpoint Research Roadmap
Tuberculosis Biomarker and Surrogate Endpoint Research Roadmap
复制标题
DOI：
10.1164/rccm.201105-0827ws
复制
发表时间：
2011-10-15
影响因子：
24.7
通讯作者：
Burman, William
中科院分区：
文献类型：
--
作者：
Nahid, Payam;Saukkonen, Jussi;Burman, William
美国疾病控制与预防中心和国立卫生研究院召开了一次多学科会议，讨论结核病治疗反应的替代标志物。目的是评估最近的替代标记物研究，并为以下方面提供具体建议：(1)治疗结果生物标记物的鉴定和验证；(2)未来临床试验标本和数据采集的标准化，包括最小样本集和采集时间点；(3)建立标本库以支持生物标记物检测。本文总结了这些建议，并提供了实现这些建议的路线图。
The Centers for Disease Control and Prevention and National Institutes of Health convened a multidisciplinary meeting to discuss surrogate markers of treatment response in tuberculosis. The goals were to assess recent surrogate marker research and to provide specific recommendations for (1) the qualification and validation of biomarkers of treatment outcome; (2) the standardization of specimen and data collection for future clinical trials, including a minimum set of samples and collection time points; and (3) the creation of a specimen repository to support biomarker testing. This article summarizes these recommendations and provides a roadmap for their implementation.